Medicare to Cover Rosetta Genomics Diagnostic Test To Find Cancer of the Unknown Primary

It’s about time for this test to be covered as it is important.  Way back in January of 2009 I interviewed the CCO of Rosetta and he explained what this test is.  You may have cancer in your lung for example, but it may not have originated there and this test will be able to identify if it by chance came from somewhere else in your body, which makes a huge difference with treatments as one medication that treats lung cancer may be quite different from one that treats let’s say kidney cancer for an example.  Lab results can be done in 10 days or less.  You can read my original interview below for more information. 

Rosetta Genomics Interview – microRNA for Diagnosing Lung Cancer Tumors

Also, what is also unique is the fact that Rosetta’s tests use Formalin Fixed Paraffin Embedded (FFPE) tissue samples, whereby the tissue is saved in a container that does not require any type of special care other than room temperature and the lab can use the 3-10 slices to extract the microRNA without any additional issues for a physician to deal with
.
By knowing quickly and accurately the origin of the metastases, doctors can come up with a guided treatment plan and remove much of the trial and error with drugs and choose therapies that are specifically targeted for the type of cancer to be treated.


Rosetta works with MicroRNA and has a data base that goes back to the year 2000.    MicroRNAs are now being considered “The Master Switch of the Body”, Mr. Tamir stated, and by determining the level of expression of specific MicroRNAs, we can make diagnostic decisions.  BD  

---

Rosetta Genomics Ltd. (NASDAQ: ROSG)announced that Novitas, the designated Medicare Administrative Contractor for the Company’s miRview(R) mets^2 assay, has informed Rosetta that it plans to cover this assay for all Medicare beneficiaries. MiRview(R) mets^2 accurately identifies the primary tumor of origin in primary and metastatic cancer including Cancer of Unknown or Uncertain Primary (“CUP”).

The policy will cover the 45 million Medicare beneficiaries and will enable Rosetta to provide the miRview(R) mets2 assay for Medicare beneficiaries throughout the U.S. at no cost to the patient, thereby eliminating an adoption barrier for the physician ordering the test and for the patient. miRview(R)

Products are a series of microRNA-based diagnostic products offered by Rosetta Genomics. miRview(R) mets and miRview(R) mets^2 accurately identify the primary tumor type in primary and metastatic cancer including Cancer of Unknown Primary (CUP). miRview(R) squamous accurately identifies the squamous subtype of non-small cell lung cancer, which carries an increased risk of severe or fatal internal bleeding and poor response to treatment for certain therapies. miRview(R) meso diagnoses mesothelioma, a cancer connected to asbestos exposure. miRview(R) lung accurately identifies the four main subtypes of lung cancer using small amounts of tumor cells.

miRview(R) kidney accurately classifies the four most common kidney tumors: Clear Cell Renal Cell Carcinoma (RCC), Papillary RCC, Chromophobe RCC and Oncocytoma. miRview(R) tests are designed to provide objective diagnostic data; it is the treating physician’s responsibility to diagnose and administer the appropriate treatment. In the U.S. alone, Rosetta Genomics estimates that 200,000 patients a year may benefit from the miRview(R) mets and miRview(R) mets^2 test, 60,000 from miRview(R) squamous, 60,000 from miRview(R) meso, 54,000 from miRview(R) kidney and more than 1 million patients worldwide from miRview(R) lung.


http://www.bioisrael.com/medicare-to-cover-rosetta-genomics-cancer-diagnostic